Can a calming drug combo bring clarity to cancer patients?
NCT ID NCT01949662
First seen Jun 27, 2026 · Last updated Jul 17, 2026 · Updated 1 time
Summary
This study looks at whether adding lorazepam to haloperidol can better reduce delirium (sudden confusion and agitation) in people with advanced cancer who are in a palliative care unit. About 93 participants will receive either haloperidol alone or with lorazepam, and their level of calmness and alertness will be measured. The goal is to help patients feel more comfortable and less distressed.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED CANCERS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Texas MD Anderson Cancer Center
Houston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug tame advanced solid tumors?
- Can a new targeted pill tame advanced cancers? a phase i trial seeks answers
- Magic mushroom compound tested for cancer pain that opioids Can't touch
- New antibody injection targets Hard-to-Treat lung cancer in early trial
- Experimental combo targets tough tumors
- Ginseng put to the test against cancer fatigue